A novel insulin delivery device (IDD) has been developed to deliver rapid-acting insulin over ∼3 days as a continuous infusion (basal dose) in addition to bolus doses on demand for adults with T2D (Fig.1). This evidence concerns the gene INS and type 2 diabetes mellitus.